Putting to rest concerns raised after its emergency approval earlier this month, the Lancet Infectious Disease journal published a study that said Covaxin – India’s first indigenous vaccine against Covid-19 – showed enhanced immune response without any serious side effects in the participants enrolled for the phase 1 trials.
The study comes at a time when the Indian government is being forced to draw up an elaborate plan to alleviate fears among citizens against taking the vaccine fueled by news reports of severe side-effects (none medically substantiated) in recipients.
Also read | Covid-19: Rising Reluctance to Take the Shot Latest Challenge Before Centre
Hyderabad-based Bharat Biotech, who developed the vaccine in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), Pune, welcomed the move.
“Extremely proud to announce phase I clinical trial studies of Covaxin, published in the most prestigious journal of THE…
